Pharmacokinetics of cefotaxime.

Antimicrobial Agents and Chemotherapy
K P FuH C Neu

Abstract

The pharmacokinetics of cefotaxime after intramuscular injection and intravenous infusion were determined. The mean peak serum level after the 500-mg intramuscular dose was 11.7 micrograms/ml, and it was 20.5 micrograms/ml after a 1,000-mg dose. The serum half-life was 1.2 and 1.3 h, respectively for the two doses. The apparent fractional volumes of distribution of 32 and 37 liters were not significantly different for the two doses, and the fractional serum clearance was approximately 315 ml/min per 1.73 m2 for both doses. The mean peak serum level after 1,000 mg administered by intravenous infusion over 30 min was 41.1 micrograms/ml. The half-life was 1.13 h, apparent volume of distribution was 33 liters, serum clearance 341 ml/min per 1.73 m2, and renal clearance was 130 ml/min per 1.73 m2. The pharmacology of cefotaxime is similar to the pharmacology of other cephalosporin antibiotics, but the low inhibitory levels which it has against gram-positive and gram-negative bacteria suggest that lower dosage regimens should be possible.

References

Jul 1, 1976·Journal of Pharmaceutical Sciences·A J Sedman, J G Wagner
Sep 1, 1978·The Journal of Antimicrobial Chemotherapy·F A DrasarJ D Williams
Jan 1, 1978·Antibiotics and Chemotherapy·J M BrogardM Pinget
May 1, 1978·The Journal of Infectious Diseases·H C Neu
Dec 1, 1975·Journal of Pharmaceutical Sciences·C H NightingaleR Quintiliani
Mar 1, 1966·Applied Microbiology·J V BennettW M Kirby

❮ Previous
Next ❯

Citations

Nov 1, 1982·Bulletin of the New York Academy of Medicine·B Farber, R C Moellering
Apr 1, 1987·European Journal of Drug Metabolism and Pharmacokinetics·E BeyssacJ M Aiache
Jul 1, 1989·Diagnostic Microbiology and Infectious Disease·B Wiedemann, K Peter
May 1, 1995·Diagnostic Microbiology and Infectious Disease·K B PatelR Quintiliani
Feb 1, 1981·Antimicrobial Agents and Chemotherapy·S SrinivasanH C Neu
May 1, 1981·Antimicrobial Agents and Chemotherapy·M L SimpsonD I Wigren
Sep 1, 1981·Antimicrobial Agents and Chemotherapy·H C Neu, S Srinivasan
Sep 1, 1981·Antimicrobial Agents and Chemotherapy·S Srinivasan, H C Neu
Oct 1, 1981·Antimicrobial Agents and Chemotherapy·D A KafetzisC J Papadatos
Nov 1, 1981·Antimicrobial Agents and Chemotherapy·R LüthyW Siegenthaler
Jan 1, 1982·Antimicrobial Agents and Chemotherapy·P H KarakusisG M Trenholme
Feb 1, 1982·Antimicrobial Agents and Chemotherapy·C J Schleupner, J C Engle
Jul 1, 1982·Antimicrobial Agents and Chemotherapy·K S IsraelK A DeSante
Aug 1, 1982·Antimicrobial Agents and Chemotherapy·H MatsuiT Okuda
Jan 1, 1983·Antimicrobial Agents and Chemotherapy·M OhkawaK Kuroda
Mar 1, 1983·Antimicrobial Agents and Chemotherapy·B KemmerichP Koeppe
Aug 1, 1983·Antimicrobial Agents and Chemotherapy·I GarciaG P Bodey
Jul 1, 1985·Antimicrobial Agents and Chemotherapy·J C EngleC J Schleupner
Dec 1, 1985·Antimicrobial Agents and Chemotherapy·J M TrangR B Kluza
Apr 1, 1983·The British Journal of Venereal Diseases·G A de KoningB van Klingeren
Sep 1, 1989·Infection·R F Jacobs, G L Kearns
Mar 1, 1982·The Journal of Pediatrics·D A KafetzisC J Papadatos
Sep 4, 2014·The Journal of Antimicrobial Chemotherapy·Thea S B KjeldsenJohn E Olsen
Nov 25, 2004·Transplantation Proceedings·X SunY Li
Oct 1, 2016·European Journal of Drug Metabolism and Pharmacokinetics·Mosab ArafatMomir Mikov
Jan 12, 2008·European Journal of Gastroenterology & Hepatology·Valérie Dhalluin-VenierGilles Pelletier

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Antimicrobial Agents and Chemotherapy
R LüthyW Siegenthaler
The Journal of Antimicrobial Chemotherapy
D S ReevesR P Bax
© 2021 Meta ULC. All rights reserved